ClinicalTrials.gg
RecruitingNCT06440993Updated Oct 23, 2026

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma

A Phase 2 interventional study of Gemcitabine and Cisplatin in Extrahepatic Cholangiocarcinoma and Unresectable Perihilar or Ductal CCA, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 12 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know · 7 judgments

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Oct 23, 2026Site recruiting status changedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing durvalumab in Cholangiocarcinoma — 14 open to participants now, 18 under way, none of them phase 3. durvalumab · Cholangiocarcinoma.

Planned enrollment
6th of 21
42 · median 33
Started
2024
with 8 others
Phase 2
18 of 21
12 open now
Primary completion
2027-01
later than 10 of 17 live
Registered
14th of 21
by date
Lead sponsor
2 of 21
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Among the 21 studies testing durvalumab in Cholangiocarcinoma, this one is the 6th largest by planned enrollment, is one of 9 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 10 of the 17 other live ones, and was the 14th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

14 of the 21 studies testing durvalumab in Cholangiocarcinoma are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing durvalumab in Cholangiocarcinoma, or all of them as a file.
02

Study summary

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal or intrahepatic CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled.

We hypothesize that in patients with extra- and intrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.

03

Conditions studied

  • Extrahepatic Cholangiocarcinoma
  • Unresectable Perihilar or Ductal CCA

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient* has given written .
  2. Patient is ≥ 18 years of age at time of signing the written informed consent.
  3. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  4. Patient has been diagnosed with or cytologically confirmed

    1. histologically or cytologically confirmed cholangiocarcinoma as adenocarcinoma of pancreatobiliary type
    2. unresectable perihilar and/or ductal extrahepatic cholangiocarcinoma or intrahepatic CCA with perihilar stricture according to Bismuth-Corlette classification with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent
  5. Patient tolerated RFA prior to inclusion and is eligible for repeat RFA during the study (does not have any ) as determined by investigator.
  6. Patient is eligible for palliative systemic therapy based on clinical and laboratory parameters (except hyperbilirubinemia) as determined by the local MDT
  7. Patient has a ≤ 1.
  8. Patient has of ≥ 12 weeks
  9. Patient has body weight > 30 kg
  10. Adequate blood count, liver-enzymes, and renal function:

    1. > 1,500 cells/μL without the use of hematopoietic growth factors
    2. count ≥ 100 x 109/L (>100,000 per mm3)
    3. ≥ 9 g/dL
    4. Serum total ≤ 3x upper normal limit () (biliary drainage is allowed for biliary obstruction; elevated bilirubin should be caused by obstruction not impaired liver function as assessed by albumin and values)
    5. Albumin levels ≥ 2.8 g/dL
    6. Patients not receiving therapeutic anticoagulation must have an INR\< 2.0 ULN and PTT \< 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of inclusion
    7. (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN unless liver are present, in which case it must be ≤ 5x ULN
    8. Serum Creatinine ≤ 1.5 x ULN and a calculated rate ≥ 60 mL /min
  11. Female patients defined as women of (WOCBP) or male patients with WOCBP partners must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last dose of chemotherapy or for at least 3 months after last dose of durvalumab, whatever happens last. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.

Exclusion criteria

Exclusion Criteria:

  1. Patient received previous or simultaneous endobiliary treatment other than RFA (e.g. PDT or brachytherapy)
  2. Patient received previous systemic therapy with a , PD-L1 inhibitor (including durvalumab) or CTLA4 inhibitor or classical chemotherapy agents like platinum, fluoropyrimidine or gemcitabine-based regimens.
  3. Patient receives any concurrent chemotherapy, product or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g., hormone replace therapy) is acceptable.
  4. Patient has known to any component of the durvalumab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein and/or any known (including hypersensitivity) to gemcitabine or cisplatin.
  5. Patient has history of primary immunodeficiency
  6. Patient has stage B cirrhosis according to criteria (or worse) or cirrhosis (of any grade) with a history of hepatic encephalopathy or ascites resulting from cirrhosis. Clinically significant ascites is defined as ascites resulting from cirrhosis requiring diuretics or paracentesis.
  7. Patient has any unresolved grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and laboratory values defined in the inclusion criteria

    1. Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Lead Investigator
    2. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Lead Investigator.
  8. Patient had a prior bone marrow transplantation or prior solid organ transplantation.
  9. Patient has active or history of or inflammatory disorders (including, but not limited to, inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis]) . The following are exceptions:

    1. Patients with vitiligo or alopecia
    2. Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
    3. Patients with any chronic skin condition that does not require systemic therapy
    4. Patients with celiac disease controlled by diet alone
    5. Patients without active disease in the last 5 years may be included but only after consultation with the Lead Investigator
  10. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    systemic plus ID-RFA

    systemic treatment: - combination treatment for 8 cycles (Q3W): * Gemcitabine, 1,000 mg/m2 IV, on day 1 and 8, * Cisplatin, 25 mg/m2 IV, on day 1 and 8 * Durvalumab, 1,500 mg IV, on day 1 followed by * Durvalumab maintenance, 1,500 mg IV, PLUS • 2 endoscopic intraductal RFA

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Durvalumab · Procedure: ID-RFA

Interventions

  • Gemcitabine, 1,000 mg/m2 IV

  • Cisplatin, 25 mg/m2 IV

  • Durvalumab, 1,500 mg IV

  • ProcedureID-RFA

    endoscopic intraductal RFA

06

What researchers measure

Primary outcomes

  1. Overall survival rate

    Overall survival rate after 12 months (OS@12months) defined as proportion of patients alive 12 months after enrollment

    Time frame: at 12 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) defined as time from enrollment to the date of disease progression or death from any cause

    Time frame: at study end

  2. Overall survival (OS)

    Overall survival (OS) Defined as time from enrollment to the date of death from any cause

    Time frame: at study end

  3. Incidence and nature of adverse events using NCI CTCAE 5.0

    Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5.0

    Time frame: through study completion, up to 3years

  4. Time to cholangitis

    Time to cholangitis Defined as time from enrollment to the date of confirmed cholangitis

    Time frame: from enrollment to first cholangitis event, up to 3 years

  5. To assess quality of life (QoL) data from patients using EORTC QLQ-BIL21

    To assess quality of life (QoL) data from patients using EORTC QLQ-BIL21

    Time frame: through study completion, up to 3years

  6. To assess quality of life (QoL) data from patients using EORTC QLQ-C30

    To assess quality of life (QoL) data from patients using EORTC QLQ-C30

    Time frame: through study completion, up to 3years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 29 months after the start.

Of 147 non-industry phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 29 months is below that.

Counting every sponsor, half of 173 studies reached it within 46 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. Universitätsklinik Münster is now Recruiting
Show 2 added (2 Germany)
  • Kliniken Köln · Cologne, Germany
  • Evangelisches Krankenhaus Düsseldorf · Düsseldorf, Germany
Oct 23, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Editedunresectable perihilar and/or ductal extrahepatic cholangiocarcinoma or intrahepatic CCA with perihilar stricture according to Bismuth-Corlette classification with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent
Oct 23, 2026
Title
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in ExtrahepaticExtra- and Intrahepatic Cholangiocarcinoma
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    2 sites added. Universitätsklinik Münster is now Recruiting
    Show 2 added (2 Germany)
    • Kliniken Köln · Cologne, Germany
    • Evangelisches Krankenhaus Düsseldorf · Düsseldorf, Germany
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Editedunresectable perihilar and/or ductal extrahepatic cholangiocarcinoma or intrahepatic CCA with perihilar stricture according to Bismuth-Corlette classification with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT) and already resolved cholestasis due to RFA + stent
    Title Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in ExtrahepaticExtra- and Intrahepatic Cholangiocarcinoma
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06440993
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Universitätsklinikum Düsseldorf, Germany, Universitätsklinikum Köln, AstraZeneca
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Aug 23, 2024
Primary completion
Jan 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Christoph Roderburg, Prof. Dr.
Contact
christoph.roderburg@med.uni-duesseldorf.de
+49 211 8108030
Johanna Riedel, Dr.
Contact
clean-duct@ikf-khnw.de
+49 69 5899 787 ext. 57
Salah-Eddin SE Al-Batran, Prof. Dr.
study chair · Frankfurter Institut fuer Klinische Krebsforschung IKF GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion